Access & Pricing at the World Orphan Drug Congress

 

Strategy, advocacy and partnering for the orphan drug industry

2-5 November 2020

Melia Sitges Hotel Resort, Barcelona, Spain

 

 
700+
Attendees
350+
Companies
200+
Speakers
80%
Decision Makers
2
Co-located events

Access & Pricing

 

➤  Defining the value of orphan drugs from societal impact to pricing models

➤  Pre-approval access, a key component of your strategic rare disease drug development

➤  RWE models supporting patient access to new therapies

➤  What is the relationship between price and prevalence in rare diseases?

➤  The framework for conducting and tracking commercial negotiations in HTA

➤  Cross-country collaboration on evidence generation from Beneluxa, V4+, Nordics and the Valetta declaration

2019 KEY SPEAKERS

 

Inneke Van De Vijver , Advisor , N.I.H.D.I.

Inneke Van De Vijver | Advisor | N.I.H.D.I. » speaking at Orphan Drug Congress

Amr Makady , Pharmacoeconomics Advisor , Zorginstituut Nederland

Amr Makady | Pharmacoeconomics Advisor | Zorginstituut Nederland » speaking at Orphan Drug Congress

Christopher Fearne , Minister , Minister For Health

Christopher Fearne | Minister | Minister For Health » speaking at Orphan Drug Congress

Dr Marcin Czech , Vice Minister, Poland , Ministry of Health

Dr Marcin Czech | Vice Minister, Poland | Ministry of Health » speaking at Orphan Drug Congress

Mercedes Echauri , Head Of International Access Innovation , Takeda

Mercedes Echauri | Head Of International Access Innovation | Takeda » speaking at Orphan Drug Congress

Dennis Akkaya, Corporate Development, myTomorrows

Dennis Akkaya | Corporate Development | myTomorrows » speaking at Orphan Drug Congress

Karen Facey, Senior Research Fellow, University of Edinburgh

Karen Facey | Senior Research Fellow | University of Edinburgh » speaking at Orphan Drug Congress